MASHINIi

Oncolytics Biotech Inc..

ONCY.US | Research and experimental development on natural sciences and engineering

Oncolytics Biotech Inc. is a biopharmaceutical company focused on the development and commercialization of oncolytic viruses as potential cancer therapeutics. The company's primary focus is on pelareorep, an intravenously delivered immuno-oncolytic virus. Oncolytics Biotech conducts clinical trials ...Show More

Ethical Profile

Mixed.

Oncolytics Biotech Inc. focuses on developing cancer treatments like pelareorep for breast, pancreatic, and anal cancers, aiming to improve global health outcomes. However, reports suggest the company likely conducts animal testing during preclinical drug development, a practice critics point to as conflicting with 'Kind to Animals' values. Specific data on the volume or types of animals used, or efforts to reduce testing, are not publicly available. For areas like fair pay, ethical sourcing, environmental impact, or community engagement, there is insufficient public information to assess the company's practices.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-60
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech-40
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess Oncolytics Biotech Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

No evidence available to assess Oncolytics Biotech Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess Oncolytics Biotech Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

Oncolytics Biotech Inc. is a biopharmaceutical company focused on research and development, clinical trials, and regulatory approvals, and does not manufacture or sell commercial products at this stage.

1
The provided articles contain no information regarding fair trade certifications, audit frequency for suppliers, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in supplier contracts, or high-risk material sourcing.
2
Given the company's operational focus on R&D rather than commercial manufacturing or trading of physical commodities, all KPIs related to these aspects of fair trade and ethical sourcing are deemed N/A.

Honest & Fair Business

0

No evidence available to assess Oncolytics Biotech Inc. on Honest & Fair Business.

Kind to Animals

-60

Oncolytics Biotech Inc. explicitly states that it exploits animals for product testing for its product, REOLYSIN®, indicating that no products are certified cruelty-free.

1
The company's policy on animal testing is vague, acknowledging the use of animals for product testing without providing details on reduction efforts, alternative methods, or specific ethical guidelines.
2
There is no evidence of the company employing non-animal testing methods, investing in animal-free technologies, or participating in collaborative initiatives for animal-free testing standards.
3
Furthermore, no information is available regarding the volume of animals used in testing or any engagement in public policy advocacy for animal welfare.
4

No War, No Weapons

0

Oncolytics Biotech Inc. is a biopharmaceutical company focused on the research and development of cancer therapeutics.

1
The provided articles exclusively detail its activities in cancer immunotherapy and general corporate information. No evidence was found in any of the articles regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding initiatives, or any other activities related to the 'No War, No Weapons' ethical value. Therefore, no KPIs could be scored.

Planet-Friendly Business

0

The provided articles consistently focus on Oncolytics Biotech Inc.'s financial performance, clinical trial results, and corporate governance. None of the articles contain specific, concrete data points or information related to any of the 'Planet-Friendly Business' key performance indicators, such as carbon emissions, renewable energy use, water consumption, waste management, or climate-related policies and initiatives.

1
Therefore, no KPIs can be scored based on the evidence provided.

Respect for Cultures & Communities

0

Oncolytics Biotech Inc. has no reported cultural appropriation incidents.

1
The company's Code of Ethics provides a grievance mechanism through contact with the Chairman of the Audit Committee, which serves as a standard process.
2
Given the company's focus on biopharmaceutical research and development, several KPIs related to direct community impact, cultural sites, FPIC processes, and specific cultural investments are not applicable to its business model. No evidence was found regarding formal partnerships with indigenous or local community groups, revenue reinvested locally, local employment ratios, complaint resolution times, local procurement, or specific cultural training.
3

Safe & Smart Tech

-40

The company explicitly states it faces "compliance challenges" with several major data protection laws and regulations, including CCPA, HIPAA, GDPR, and UK GDPR.

1
Furthermore, as a clinical-stage biotech, it is "not yet in a position to implement a broad-based ESG policy and program,"
2
which suggests a less mature approach to overall governance, including privacy and data security compliance.

Zero Waste & Sustainable Products

0

No evidence available to assess Oncolytics Biotech Inc. on Zero Waste & Sustainable Products.

Own Oncolytics Biotech Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.